ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Alkermes plc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$42.97+1.75 (+4.25%)

Close on Oct 19, 2026

Market cap: $7.45B
P/E (TTM): 113.1
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$1.48BFY2025, +16.3% a year since FY2010

Where these numbers come from

Parsed from the XBRL in Alkermes's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on May 15, 2000
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALKS.

Revenue growth10.8% · median 13.5%

Gross margin84.6% · median 88.1%

Operating margin7.0% · median 7.6%

Net margin4.0% · median 5.0%

Company	Revenue	Growth
AMRX	$3.12B	+9.3%
ALKS	$1.67B	+10.8%
INDV	$1.33B	+13.5%
ACAD	$1.14B	+11.8%
SUPN	$830.44M	+24.9%
AXSM	$776.57M	+56.9%

Company

Next earnings (est.): Oct 27, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 2,050
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1520262

Advertisement
300 × 250